Bisphosphonate-based strategies for bone tissue engineering and orthopedic implants

Tissue Engineering - Part B: Reviews

Volumn 18, Issue 5, 2012, Pages 323-340

  Cattalini, Juan Pablo ^a   Boccaccini, Aldo R ^b   Lucangioli, Silvia ^c   Mouriño, Viviana ^a,c  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Universidad Nacional de Río Cuarto Consejo Nacional de Investigaciones Científicas y Técnicas   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

3D SCAFFOLDS; BISPHOSPHONATES; BONE REGENERATION; BONE TISSUE ENGINEERING; BONE TISSUE SCAFFOLDS; ORTHOPEDIC IMPLANT; RESEARCH EFFORTS; SUSTAINED RELEASE; THERAPEUTIC DRUGS;

BONE; DRUG THERAPY; THREE DIMENSIONAL COMPUTER GRAPHICS; TISSUE;

SCAFFOLDS (BIOLOGY);

ALENDRONIC ACID; ALGINIC ACID; ALKALINE PHOSPHATASE; BIOMATERIAL; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM PHOSPHATE; CHITOSAN; CLODRONIC ACID; COLLAGEN; COLLAGEN TYPE 1; COPOLYMER; DRUG CARRIER; ETIDRONIC ACID; HYDROXYAPATITE; LIPOSOME; MACROGOL; MICROSPHERE; NANOPARTICLE; OSTEOCALCIN; PAMIDRONIC ACID; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIDE; POLYMER; RISEDRONIC ACID; SILICON DIOXIDE; STARCH; TILUDRONIC ACID; TISSUE SCAFFOLD; ZOLEDRONIC ACID;

ANALYTIC METHOD; ARTICLE; BONE ATROPHY; BONE MATRIX; BONE MINERAL; BONE TISSUE; CAPILLARY ZONE ELECTROPHORESIS; CELL DIFFERENTIATION; CELL GROWTH; CHEMICAL COMPOSITION; COMPOSITE MATERIAL; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG MEGADOSE; EVAPORATIVE LIGHT SCATTERING DETECTION; FRACTURE HEALING; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; IMPLANT; INFLAMMATORY DISEASE; JAW OSTEONECROSIS; LIMIT OF DETECTION; LIMIT OF QUANTITATION; METABOLIC BONE DISEASE; NONHUMAN; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; PAGET BONE DISEASE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PHOTOACOUSTIC MICROSCOPY; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SUSTAINED DRUG RELEASE; TISSUE ENGINEERING; X RAY PHOTOELECTRON SPECTROSCOPY;

BONE AND BONES; DIPHOSPHONATES; HUMANS; PROSTHESES AND IMPLANTS; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 84866867479     PISSN: 19373368     EISSN: 19373376     Source Type: Journal    
DOI: 10.1089/ten.teb.2011.0737     Document Type: Article

References (173)

1. Laurencin, C., Ambrosio, A., Borden, M., and Cooper, J. Tissue engineering: orthopedic applications. Annu Rev Biomed Eng 1, 19, 1999.
2. Wozney, J.M., and Seeherman, H.J. Protein-based tissue engineering in bone and cartilage repair. Curr Opin Biotechnol 15, 392, 2004.
3. Mouriñ o, V., and Boccaccini, A. Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffolds. J R Soc Interface 7, 209, 2010.
4. Baroli, B. From natural bone graft to tissue engineering therapeutics: brainstorming on pharmaceutical formulative requirements and challenges. J Pharm Sci 98, 1317, 2009.
5. van Beek, E., Hoekstra, M., van de Ruit, M., Lowik, C., and Papapoulos, S. Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res 9, 1875, 1994.
6. Rodan, G. Mechanism of action of bisphosphonates. Annu Rev Pharmacol Toxicol 38, 375, 1998.
7. Shi, X., Wang, Y., Ren, L., Gong, Y., and Wang, D. Enhancing Alendronate Release from a Novel PLGA/Hydroxyapatite Microspheric System for Bone Repairing Applications. Pharm Res 26, 422, 2009.
8. Fleisch, H. Bisphosphonates in Bone Disease: From the Laboratory to the Patient. New York, NY: The Parthenon Publishing Group, 1997.
9. Fleisch, H. Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med 29, 55, 1997.
10. Ezra, A., and Golomb, G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 42, 175, 2000.
11. Recker, R., Lewiecki, M., Miller, P., and Reiffel, J. Safety of bisphosphonates in the treatment of osteoporosis. Am J Med 122, 22, 2009.
12. Papapoulos, S. Bisphosphonate actions: physical chemistry revisited. Bone 38, 613, 2006.
13. Benedict, J. The physical chemistry of the diphosphonates-Its relationship to their structural activity. In: Donath, A., and Courvoisier, B., eds. Symposium CEMO IV. Nyon Switzerland, Geneva: EditionsMedecine estHygiene, 1982, pp. 1-19.
14. van Beek, E., Lowik, C., Ebetino, F., and Papapoulos, S. Binding and antiresorptive properties of heterocyclecontaining bisphosphonate analogs: structure-activity relationships. Bone 23, 437, 1998.
15. van Beek, E., Lowik, C., Que, I., and Papapoulos, S. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. J Bone Miner Res 11, 1492, 1996.
16. Amin, D., Cornell, S., Gustafson, S., Needle, S., Ulich, J., Bilder, G., and Perrone, M. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33, 1657, 1992.
17. Benfold, H., Frich, J., Auriola, S., Monkkonen, J., and Rogers, M. Farnesol and geranylgeraniol prevent activation of caspases by amino bisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 56, 131, 1999.
18. Frith, J., Monkkonen, J., Blackburn, G., Russell, R., and Rogers, M. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5¢-(beta, gammadichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12, 1358, 1997.
19. Green, J., and Rogers, M. Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev Res 55, 210, 2002.
20. Coleman, R. Bisphosphonates in breast cancer. Ann Oncol 16, 687, 2005.
21. Black, D., Delmas, P., Eastell, R., Reid, I., Boonen, S., Cauley, J., Cosman, F, Lakatos, P., Chung Leung, P., Man, Z., Mautalen, C., Mesenbrink, P., Hu, H., Caminis, J., Tong, K., Rosario-Jansen, T., Krasnow, J., Hue, T., Sellmeyer, D., Fink Eriksen, E., and Cummings, S. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356, 1809, 2007.
22. Rauch, F., and Glorieux, F. Osteogenesis imperfecta, current and future medical treatment. Am J Med Genet C Semin Med Genet 139, 31, 2005.
23. Borah, B., Ritman, E., Dufresne, T., Jorgensen, S., Liu, S., Sacha, J., Phipps, R., and Turner, R. The effect of risedronate on bone mineralization as measured by microcomputed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover. Bone 37, 1, 2005.
24. Little, D., McDonald, M., Bransford, R., Godfrey, C., and Armanat, N. Manipulation of the anabolic and catabolic responsens with OP-1 and zoledronic acid in a rat critical defect model. J Bone Miner Res 20, 2044, 2005.
25. Russell, R., Watts, N., Ebetino, F., and Rogers, M. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19, 733, 2008.
26. Drake, M., Clarke, B., and Khosla, S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83, 1032, 2008.
27. Kimmel, D. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86, 1022, 2007.
28. Cremers, S., Pillai, G., and Papapoulos, S. Pharmacokinetics/ pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44, 551, 2005.
29. Su, K., Shi, X., Varshney R., and Wang, D. Transplantable delivery systems for in situ controlled release of bisphosphonate in orthopedic therapy. Expert Opin Drug Deliv 8, 113, 2011.
30. Grey, A., and Reid, I. Differences between the bisphosphonates for the prevention and treatment of osteoporosis. Ther Clin Risk Manag 2, 77, 2006.
31. Perugini, P., Genta, I., Conti, B., Modena, T., and Pavanetto, F. Long-term release of clodronate from biodegradable microspheres. AAPS PharmSciTech 2, 6, 2001.
32. Josse, S., Faucheux, C., Soueidan, A., Grimandi, G., Massiot, D., Alonso, B., Janvier, P., Laib, S., Pilet, P., Gauthier, O., D, G., Guicheux, J., Bujoli, B., and Bouler, J. Novel biomaterials for bisphosphonate delivery. Biomaterials 26, 2073, 2005.
33. Peter, B., Pioletti, D., Laib, S., Bujoli, B., Pilet, P., Janiver, P., Guicheux, J., Zambelli, P., Bouler, J., and Gauthier, O. Calcium phosphate drug delivery system: Influence of local zoledronate release on bone implant osteointegration. Bone 36, 52, 2004.
34. Seshima, H., Yoshinari, M., Takemoto, S., Hattori, M., Kawada, E., Inoue, T., and Oda, Y. Control of Bisphosphonate Release Using Hydroxyapatite Granules. J Biomed Mater Res B Appl Biomater 78, 215, 2006.
35. Colilla, M., Izquierdo-Barba, I., and Vallet-Reg?́, M. Novel biomaterials for drug Delivery. Expert Opin Ther Pat 18, 639, 2008.
36. Faucheux, C., Verron, E., Soueidan, A., Josse, S., Arshad, M., Janvier, P., Pilet, P., Bouler, J., Bujoli, B., and Guicheux, J. Controlled release of bisphosphonate from a calcium phosphate biomaterial inhibits osteoclastic resorption in vitro. J Biomed Mater Res A 89, 46, 2008.
37. Roussière, H., Fayon, F., Alonso, B., Rouillon, T., Schnitzler, V., Verron, E., Guicheux, J., Petit, M., Massiot, D., Janvier, P., Bouler, J., and Bujoli, B. Reaction of Zoledronate with b-Tricalcium Phosphate for the Design of Potential Drug Device Combined Systems. Chem Mater 20, 182, 2008.
38. Cartmell, S. Controlled Release Scaffolds for Bone Tissue Engineering. J Pharm Sci 98, 430, 2009.
39. Katsumi, H., Kusamori, K., Sakane, T., and Yakamoto, A. Development of delivery system of bisphosphonates for the treatment of osteoporosis. Yakugaku Zasshi 130, 1129, 2010.
40. Kim, C., Yun, Y., Lee, H., Hwang, Y., Kwon, I., and Lee, S. In situ fabrication of alendronate-loaded calcium phosphate microspheres: Controlled release for inhibition of osteoclastogenesis. J Control Release 147, 45, 2010.
41. Verron, E., Khairoun, I., Guicheux, J., and Bouler, J. Calcium phosphate biomaterials as bone drug delivery systems: a review. Drug Discov Today 15, 547, 2010.
42. Sikavitsas, V., Temenoff, J., and Mikos, A. Biomaterials and bone mechanotransduction. Biomaterials 22, 2581, 2001.
43. Baron, R. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 2nd edition. New York, NY: Raven Press, 1993.
44. Temenoff, J., Lu, L., and Mikos, A. Bone Engineering. Em squared: Toronto 1999, p. 454.
45. Swetha, M., Sahithi, K., Moorthi, A., Srinivasan, N., Ramasamy, K., and Selvamurugan, N. Biocomposites containing natural polymers and hydroxyapatite for bone tissue Engineering. Int J Biol Macromol 47, 1, 2010.
46. Stevens, M. Biomaterials for bone tissue engineering. Mater today 11, 18, 2008.
47. Fleisch, H. Bisphosphonates: mechanisms of action. Endcr Rev 19, 80, 1998.
48. Hughes, D., MacDonald, B., Russell, R., and Gowen, M. Inhibition of osteoclast-like cell formation by bisphosphonates in long term cultures of human bone marrow. J Clin Invest 83, 1930, 1989.
49. Carano, A., Teitlebaum, S., Konsek, J., Schlesinger, P., and Blair, H. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 85, 456, 1990.
50. Reszka, A., Halasy-Nagy, J., Masarachia, P., and Rodan, G. Bisphosphonates act directly ion the osteoclast to induce caspase cleavage of mst 1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 274, 34967, 1999.
51. Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D., Glub, E., and Rodan, G. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88, 2095, 1991.
52. Murakami, H., Takahashi, N., Sasaki, T., Udagawa, N., Tanaka, S., Nakamura, I., Zhang, D., Barbier, A., and Suda, T.A possible mechanism of the specific action of bisphosphonates on osteoclasts: tildronate preferentially affects polarized osteoclasts having ruffled borders. Bone 17, 37, 1995.
53. Fisher, J., Rogers, M., Halasy, J., Luckman, S., Hughes, D., Masarachia, P., Wesolowski, G., Russell, R., Rodan, G., and Reszka, A. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96, 133, 1999.
54. Li, E., and Davis, L. Zoledronic acid: a new parenteral bisphosphonate. Clin Ther 25, 2669, 2003.
55. Reinholz, G., Getz, B., Pederson, L., Sanders, E., Subramaniam, M., Ingle, J., and Spelsberg, T. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60, 6001, 2000.
56. Sahni, M., Guenther, H., Fleisch, H., Collin, P., and Martin, T. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91, 2004, 1993.
57. Vitte, C., Fleisch, H., and Guenther, H. Bisphosphonates induce osteoblasts to secret an inhibitor of osteoclast-mediated resorption. Endocrinology 137, 2324, 1996.
58. Sanderes, J., Tarjan, G., Foster, S., and Stern, P. Alendronate/ interleukin-1b cotreatment increases interleukin-6 in bone and UMR-106 cells: dose dependence and relationship to the antiresorptive effect of alendronate. J Bone Miner Res 13, 786, 1998.
59. Garc?́a-Moreno, C., Serrano, S., Nacher, M., Farre, M., D?́ez, A., Marinoso, M., Carbonell, J., Mallibovsky, L., Nogués, X., Ballester, J., and Aub?́a J. Effect of alendronate on cultured normal human osteoblasts. Bone 22, 233, 1998.
60. Kajiwara, H., Yamaza, T., Yoshinari, M., Goto, T., Iyama, S., Atsuta, I., Kido, M., and Tanaka, T. The bisphosphonate pamidronate on the surface of titanium stimulates bone formation around tibial implants in rats. Biomaterials 26, 581, 2005.
61. Aspenberg, P. Bisphosphonates and implants an overview. Acta Orthop 80, 119, 2009.
62. Wermelin, K., Tengvall, P., and Aspenberg, P. Surfacebound bisphosphonates enhance screw fixation in rats-increasing effect up to 8 weeks after insertion. Acta Orthop 78, 385, 2007.
63. Hench, L., and Polak, J. Third-Generation Biomedical Materials. Science 295, 1014, 2002.
64. Hench, L., and Thompson I. Twenty-first century challenges for biomaterials. J R Soc Interface 7, 379, 2010.
65. Vallet-Reg?́, M., Ruiz-González, L., and Izquierdo-Barba, I., and González-Calbet, J. Revisiting silica based ordered mesoporous materials: medical applications. J Mater Chem 16, 26, 2006.
66. Chen, Q., Thompson, I., and Boccaccini, A. 45S5 Bioglasssderived glass ceramic scaffolds for bone tissue engineering. Biomaterials 27, 2414, 2006.
67. Schieker, M., Seitz, H., Drosse, I., Seitz, S., and Mutschler, W. Biomaterials as Scaffold for Bone Tissue Engineering. Eur J Trauma Emerg Surg 32, 114, 2006.
68. Jones, J., Ehrenfried, L., and Hench, L. Optimising bioactive glass scaffolds for bone tissue engineering. Biomaterials 27, 964, 2006.
69. Habraken, W., Wolke, J., and Jansen, J. Ceramic Composites as matrices and scaffolds for drug delivery in tissue engineering. Adv Drug Deliv Rev 59, 234, 2007.
70. Colilla, M., Manzano, M., and Vallet-Reg?́, M. Recent advances in ceramic implants as drug delivery systems for biomedical applications. Int J Nanomedicine 3, 403, 2008.
71. Izquierdo-Barba, I., Manzano, M., Colilla, M., and Vallet-Regi, M. Silica-based ordered mesoporous materials for biomedical applications. Key Eng Mater 377, 133, 2008.
72. Izquierdo-Barba, I., Colilla, M., and Vallet-Reg?́, M. Nanostructured mesoporous silicas for bone tissue regeneration nanostructured mesoporous silicas for bone tissue regeneration. J Nanomater 2008, 1, 2008.
73. Correlo, V., Oliveira, J., Mano, J., Neves, N., and Reis, R. Natural Origin Materials for Bone Tissue Engineering e Properties, Processing, and Performance. In: Anthony Atala, James A. Thomson, Robert Nerem, and Robert Lanza, eds. Principles of Regenerative Medicine 2nd Edition, Canada: Elsevier 2010, 557-586.
74. Sabir, M., Xu, X., and Li, L. A review on biodegradable polymeric materials for bone tissue. J Mater Sci 44, 5713, 2009.
75. Liu, X., and Ma, P. Polymeric scaffolds for bone tissue engineering. Ann Biomed Eng 32, 477, 2004.
76. Zhang, R., and Ma, P. Poly(a-hydroxyl acids)/hydroxyapatite porous composites for bone-tissue engineering. I. Preparation and morphology. J Biomed Mater Res 44, 446, 1999.
77. Lin, H., and Yeh, Y. Porous alginate/hydroxyapatite composite scaffolds for bone tissue engineering: preparation, characterization, and in vitro studies. J Biomed Mater Res B Appl Biomater 71, 52, 2004.
78. Zhang, Y., Ni, M., Zhang, M., and Ratner, B. Calcium phosphate-chitosan composite scaffolds for bone tissue engineering. Tissue Eng 9, 337, 2003.
79. Wei, G., and Ma, P. Structure and properties of nano-hydroxyapatite/ polymer composite scaffolds for bone tissue engineering. Biomaterials 25, 4749, 2004.
80. Wang, M. Composite scaffolds for bone tissue engineering. Am J Biochem Biotechnol 2, 80, 2006.
81. Kazemzadeh Narbat, M., Orang, F., Solati Hashtjin, M., and Goudarzi, A. Fabrication of porous hydroxyapatite-gelatin composite scaffolds for bone tissue engineering. Iran Biomed J 10, 215, 2006.
82. Kim, S., Park, M., Jeon, O., Choi, C., and Kim, B. Poly (lactide-co-glycolide)/hydroxyapatite composite scaffolds for bone tissue engineering. Biomaterials 27, 1399, 2006.
83. Rezwan, K., Chen, Q., Blaker, J., and Boccaccini, A. Biodegradable and bioactive porous polymer/inorganic composite scaffolds for bone tissue engineering. Biomaterials 27, 3413, 2006.
84. Chen, Q., Roether, J., and Boccaccini, A. Tissue Engineering Scaffolds from Bioactive Glass and Composite Materials. In: Ashammakhi, N., Reis, R., and Chiellini, F., eds. Topics in Tissue Engineering. Expertissues e-books, Oulu, Finland: Vol 4 2008, Chapter 6, pp. 1-27.
85. Couto, D., Hong, Z., and Mano, J. Development of bioactive and biodegradable chitosan-based injectable systems containing bioactive glass nanoparticles. Acta Biomater 5, 115, 2009.
86. Peter, M., Sudheesh K., Binulal, N., Nair, S., Tamura, H., and Jayakumar, R. Development of novel a-chitin/nanobioactive glass ceramic composite scaffolds for tissue engineering applications. Carbohydr Polym 78, 926, 2009.
87. Boccaccini, A., Erol, M., Stark, W., Mohn, D., Hong, Z., and Mano, J. Polymer/bioactive glass nanocomposites for biomedical applications: a review. Compos Sci Technol 70, 1764, 2010.
88. Peter, M., Binulal, N., Nair, S., Selvamurugan, N., Tamura, H., and Jayakumar, R. Novel biodegradable chitosan-gelatin/nano-bioactive glass ceramic composite scaffolds for alveolar bone tissue engineering. Chem Eng J 158, 353, 2010.
89. Peter, M., Binulal, N., Soumya, S., Nair, S., Furuike, T., Tamura, H., and Jayakumar, R. Nanocomposite scaffolds of bioactive glass ceramic nanoparticles disseminated chitosan matrix for tissue engineering applications. Carbohydr Polym 79, 284, 2010.
90. Hajiali, H., Karbasi, S., Hosseinalipour, M., and Reza Rezaie, H. Preparation of a novel biodegradable nanocomposite scaffold based on poly (3-hydroxybutyrate)/bioglass nanoparticles for bone tissue engineering. J Mater Sci Mater Med 21, 2125, 2010.
91. Huang, W., Shi, X., Ren, L., Du, C., and Wang, Y. PHBV microspheres-PLGA matrix composite scaffold for bone tissue engineering. Biomaterials 31, 4278, 2010.
92. Xia, W., and Chang, J. Bioactive glass scaffold with similar structure and mechanical properties of cancellous bone. J Biomed Mater Res B Appl Biomater 95, 449, 2010.
93. Arkfield, D., and Rubenstein, E. Quest for the holy grial to cure arthritis and osteoporosis: emphasis on bone drug delivery systems. Adv Drug Deliv Rev 57, 934, 2005.
94. Sheridan, M., Shea, L., Peters, M., and Mooney, D. Bioabsorbable polymer scaffolds for tissue engineering capable of sustained growth factor delivery. J Control Release 64, 91, 2000.
95. Ashammakhi, N., Ndreu, A., Yang, Y., Ylikauppila, H., and Nikkola L. Nanofiber-based scaffolds for tissue engineering. Eur J Plast Surg 35, 135, 2008.
96. Nikkola, L. Methods for controlling drug release from biodegradable matrix and development of multidrug releasing materials (Ph.D. thesis). Tampereen Teknillinen Yliopisto, Julkaisu 838, Tampere University of Technology, Publication 838, 2009.
97. Zacharis, C., and Tzanavaras, P. Determination of bisphosphonate active pharmaceutical ingredients in pharmaceuticals and biological material: a review of analytical methods. J Pharm Biomed Anal 48, 483, 2008.
98. Kline, W., Matuszewski, B., and Bayne, W. Determination of 4-amino-1-hydroxybutane-1,1-bisphosphonic acid in urine by automated precolumn derivatization with 2,3-naphthalene dicarboxyaldehyde and high-performance liquid chromatography with fluorescence detection. J Chromatogr 534, 139, 1990.
99. Kline, W., and Matuszewski, B. Improved determination of the bisphosphonate alendronate in human plasma and urine by automated precolumn derivatization and highperformance liquid chromatography with fluorescence and electrochemical detection. J Chromatogr 583, 183, 1992.
100. de Marco, J., Biffar, S., Reed, D., and Brooks, M. The determination of 4-amino-1-hydroxybutane-1,1-diphosphonic acid monosodium salt trihydrate in pharmaceutical dosage forms by high-performance liquid chromatography. J Pharm Biomed Anal 7, 1719, 1989.
101. Yun, M., and Kwon, K. High-performance liquid chromatography method for determining alendronate sodium in human plasma by detecting fluorescence: application to a pharmacokinetic study in humans. J Pharm Biomed Anal 40, 168, 2006.
102. Ptacek, P., Klima, J., and Macek, J. Determination of alendronate in human urine as 9-fluorenylmethyl derivative by high-performance liquid chromatography. J Chromatogr B 767, 111, 2002.
103. Tarcomnicu, I., Silvestro, L., Savu, S., Gherase, A., and Dulea, C. Development and application of a high-performance liquid chromatography-mass spectrometry method to determine alendronate in human urine. J Chromatogr A 1160, 21, 2007.
104. Zhu, L., Lapko, V., Lee, J., Basir, Y., Kafonek, C., Olsen, R., and Briscoe, C. A general approach for the quantitative analysis of bisphosphonates in human serum and urine by high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 20, 3421, 2006.
105. Xie, Z., Jiang, Y., and Zhang, D. Simple analysis of four bisphosphonates simultaneously by reverse phase liquid chromatography using n-amylamine as volatile ion-pairing agent. J Chromatogr A 1104, 173, 2006.
106. Al Deeb, S., Hamdan, I., and Al Najjar, S. Spectroscopic and HPLC methods for the determination of alendronate in tablets and urine. Talanta 64, 695, 2004.
107. Tsai, E., Ip, D., and Brooks, M. Determination of alendronate in pharmaceutical dosage formulations by ion chromatography with conductivity detection. J Chromatogr A 596, 217, 1992.
108. Han, Y., and Qui, X. Determination of alendronate sodium by ion chromatography with refractive index detection. J Chromatogr A 719, 345, 1996.
109. Bexheti, D., Anderson, E., Hutt, A., and Hanna-Brown, M. Evaluation of multidimensional capillary electrophoretic methodologies for determination of amino bisphosphonate pharmaceuticals. J Chromatogr A 1130, 137, 2006.
110. Prutthiwanasan, B., and Suntornsuk, L. Rapid analysis of alkylphosphonate drugs by capillary zone electrophoresis using indirect ultraviolet detection. J Sep Sci 33, 228, 2010.
111. Wong, J., Renton, K., Crocker, J., O'Regan, P., and Acott, P. The determination of pamidronate in human whole blood and urine by reversed-phase HPLC with fluorescence detection. Biomed Chromatogr 18, 98, 2004.
112. Flesch, G., Tominaga, N., and Degen, P. Improved determination of the bisphosphonate pamidronate disodium in plasma and urine by pre-column derivatization with fluorescamine, high-performance liquid chromatography and fluorescence detection. J Chromatogr B 568, 261, 1991.
113. Flesch, G., and Hauffe, S. Determination of the bisphosphonate pamidronate disodium in urine by pre-column derivatization with fluorescamine, high-performance liquid chromatography and fluorescence detection. J Chromatogr 489, 446, 1989.
114. Sparidans, R., den Hartigh, J., Beijnen, J., and Vemeij, P. Determination of pamidronate in urine by ion-pair liquid chromatography after derivatization with 1-naphthylisothiocyanate. J Chromatogr B 696, 137, 1997.
115. Sparidans, R., den Hartigh, J., Ramp-Koopmanschap, W., Langebroek, R., and Vermeij, P. The determination of pamidronate in pharmaceutical preparations by ion-pair liquid chromatography after derivatization with phenylisothiocyanate. J Pharm Biomed Anal 16, 491, 1997.
116. Sparidans, R., den Hartigh, J., Cremers, S., Beijnen, J., and Vermeij, P. Semi-automatic liquid chromatographic analysis of pamidronate in urine after derivatization with 1-naphthylisothiocyanate. J Chromatogr B 730, 95, 1999.
117. Sparidans, R., den Hartigh, J., Beijnen, J., and Vermeij, P. Semi-automatic liquid chromatographic analysis of pamidronate in serum and citrate plasma after derivatization with 1-naphthylisothiocyanate. J Chromatogr B 705, 331, 1998.
118. Hartigh, J., Langebroek, R., and Vermeij, P. Ion-exchange liquid chromatographic analysis of bisphosphonates in pharmaceutical preparations. J Pharm Biomed Anal 11, 977, 1993.
119. Sakiyama, N., Kataoka, H., and Makita, M. Selective and sensitive determination of pamidronate in human plasma and urine by gas chromatography with flame photometric detection. Biomed Chromatogr 9, 243, 1995.
120. Jiang, Y., and Xie, Z. Determination of ibandronate and its degradation products by ion-pair RP LC with evaporative light-scattering detection. Chromatographia 62, 257, 2005.
121. Jiang, Y., Zhang, X., and Xu, Z. Analysis of zoledronic acid and its related substances by ion-pair RP-LC. Chromatographia 60, 405, 2004.
122. Niemi, R., Taipale, H., Ahlmark, M., Vepsalainen, J., and Jarvinen, T. Simultaneous determination of clodronate and its partial ester derivatives by ion-pair reversed-phase highperformance liquid chromatography coupled with evaporative light-scattering detection. J Chromatogr B Biomed Sci Appl 701, 97, 1997.
123. Perjesi, P., Kim, T., Zharikova, A., Li, X., Ramesh, T., Ramasubbu, J., and Prokai, L. Determination of clodronate content in liposomal formulation by capillary zone electrophoresis. J Pharm Biomed Anal 31, 929, 2003.
124. Muntoni, E., Canaparo, R., Della Pepa, C., Serpe, L., Casale, F., Barbera, S., Romano, P., Zara, G., and Eandi, M. Determination of disodium clodronate in human plasma and urine using gas-chromatography-nitrogen- phosphorous detections: validation and application in pharmacokinetic study. J Chromatogr B 799, 133, 2004.
125. Aluoch, A., Tatini, R., Parsons, D., and Sadik, O. Stability indicating ion-pair HPLC method for the determination of risedronate in a commercial formulation. J Liq Chromatogr Relat Technol 27, 2799, 2005.
126. Kyriakides, D., and Panderi, I. Development and validation of a reversed-phase ion-pair high-performance liquid chromatographic method for the determination of risedronate in pharmaceutical preparations. Anal Chim Acta 584, 153, 2007.
127. Jia, H., Li, W., and Zhao, K. Determination of Risedronate in Rat Plasma Samples by Ion-Pair High-Performance Liquid Chromatography with UV Detector. Anal Chim Acta 562, 171, 2006.
128. Vallano, P., Shugarts, S., Kline, W., Woolf, E., and Matuszewski, B. Determination of risedronate in human urine by column-switching ion-pair high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 794, 23, 2003.
129. Josse, S., Faucheux, C., Grimandi, G., Massiot, A., Alonso, B., Janvier, P., Pilet, P., Gauthier, O., Daculsi, G., Guicheux, J., Bujoli, B., and Bouler, J. An innovative strategy for local treatment of bone resorption and prevention of osteoporotic fractures. Adv Mater 16, 1423, 2004.
130. Josse, S., Faucheux, C., Soueidan, A., Grimandi, G., Massiot, D., Alonso, A., Janvier, P., Laib, S., Gauthier, O., Daculsi, G., Guicheux, J., Bujoli, B., and Bouler, J. Chemically modified calcium phosphates as novel materials for bisphosphonate delivery. Adv Mater 16, 1423, 2004.
131. Peter, B., Gauthier, O., Laib, S., Bujoli, B., Guicheux, J., Janvier, P., van Lenthe, G., Muller, R., Zambelli, P., Bouler, J., and Pioletti, D. Local delivery of bisphosphonates from coated orthopedic implants increases implants mechanical stability in osteoporotic rats. J Biomed Mater Res A 76, 133, 2006.
132. Boanini, E., Torricelli, P., Gazzano, M., Giardino, R., and Bigi, A. Alendronate-hydroxyapatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells. Biomaterials 29, 790, 2008.
133. Välimä ki, V., Moritz, N., Yrjans, J., Vuorio, E., and Aro, H. Effect of zoledronic acid on incorporation of a bioceramic bone graft substitute. Bone 38, 432, 2006.
134. Balas, F., Manzano, M., Horcajada, P., and Vallet-Reg?́, M. Confinement and controlled release of bisphosphonates on ordered mesoporous silica-based materials. J Am Chem Soc 128, 8116, 2006.
135. Nieto, A., Balas, F., Colilla, M., Manzano, M., and Vallet-Reg?́, M. Functionalization degree of SBA-15 as key factor to modulate sodium alendronate dosage. Microporous Mesoporous Mater 116, 4, 2008.
136. Dorozhkin, S. Calcium orthophosphates. J Mater Sci 42, 1061, 2007.
137. Dorozhkin, S. Bioceramics of calcium orthophosphates. Biomaterials 31, 1465, 2010.
138. Oliveira, A., Pedro, A., Arroyo, C., Mano, J., Rodriguez, G., San Roman J., and Reis R. Biomimetic Ca-P Coatings Incorporating Bisphosphonates Produced on Starch-Based Degradable Biomaterials. J Biomed Mater Res B Appl Biomater 92, 55, 2010.
139. Patashnik, S., Rabinovich, L., and Golomb, G. Preparation and evaluation of chitosan microspheres containing bisphosphonates. J Drug Target 4, 371, 1997.
140. Puppi, D., Piras, A., Chiellini, F., Chiellini, E., Martins, A., Leonor, I., Neves, N., and Reis, R. Optimized electro-and wet-spinning techniques for the production of polymeric fibrous scaffolds loaded with bisphosphonate and hydroxyapatite. J Tissue Eng Regen Med 5, 253, 2011.
141. Lu, J., Liu, J., Song, X., Chen, X., and Wu, X. Sandwich Structure-like Meshes Fabricated via Electrospinning for Controllable Release of Zoledronic Acid. Chem Res Chin Univ 27, 524, 2011.
142. Ying, J., Mehnert, C., and Wong, M. Synthesis and applications of supramolecular-templated mesoporous materials. Angew Chem Int Ed 38, 57, 1999.
143. Soler-Illia, G., Sanchez, C., Lebeau, B., and Patarin, J. Chemical strategies to design textured materials: from microporous and mesoporous oxides to nanonetworks and hierarchical structures. Chem Rev 102, 4093, 2002.
144. Vallet-Reǵ, M., Colilla, M., and Izquierdo-Barba, I. Bioactive mesoporous silicas as controlled delivery systems: application in bone tissue regeneration. J Biomed Nanotechnol 4, 1, 2008.
145. Crank, J. The Mathematics of Diffusion 2nd Edition. New York: Oxford University Press, 1975.
146. Costa, P., and Sousa-Lobo, J. Modelling and comparison of dissolution profiles. Eur J Pharm Sci 13, 123, 2001.
147. Yu, N., Schindeler, A., Peacock, L., Mikulec, K., Baldock, P., Ruys, A., and Little, D. In vivo local co-delivery of recombinant human bone morphogenetic protein-7 and pamidronate via poly-D,L-lactic acid. Eur Cell Mater 20, 431, 2010.
148. Hirabayashi, H., and Fujisaki, J. Bone-specific drug delivery systems: approaches via chemical modification of boneseeking agents. Clin Pharmacokinet 42, 1319, 2003.
149. Hengst, V., Oussoren, C., Kissel, T., and Storm, G. Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. Int J Pharm 331, 224, 2007.
150. Anada, T., Takeda, Y., Honda, Y., Sakurai, K., and Suzuki, O. Synthesis of calcium phosphate-binding liposome for drug delivery. Bioorg Med Chem Lett 19, 4148, 2009.
151. Pignatello, R., Cenni, E., Micieli, D., Fotia, C., Salerno, M., Granchi, D., Avnet, S., Sarpietro, M., Castelli, F., and Baldini, N. A Novel Biomaterial for Osteotropic Drug Nanocarriers: synthesis and biocompatibility evaluation of a PLGA-ALE Conjugate. Nanomedicine 4, 161, 2009.
152. Wang, G., Babadag li, M., and Uludag? , H. Bisphosphonate-Derivatized Liposomes to Control Drug Release from Collagen/Hydroxyapatite Scaffolds. Mol Pharm 8, 1025, 2011.
153. Mandell, J., Carter, D., Goodman, S., Schurman, D., and Beaupre, G. A conical-collared intramedullary stem can improve stress transfer and limit micromotion. Clin Biomech 19, 695, 2004.
154. Ramaniraka, N., Rakotomanana, L., and Leyvraz, P. The fixation of the cemented femoral component. Effects of stem stiffness, cement thickness and roughness of the cement-bone surface. J Bone Joint Surg Br 82, 297, 2000.
155. Stadelmann, V., Terrier, A., and Pioletti, D. Microstimulation at the bone-implant interface upregulates osteoclast activation pathways. Bone 42, 358, 2008.
156. Karrholm, J., Borssen, B., Lowenhielm, G., and Snorrason, F. Does early micromotion of femoral stem prostheses matter? 4-7-year stereoradiographic follow-up of 84 cemented prostheses. J Bone Joint Surg Br 76, 912, 1994.
157. Hilding, M., Ryd, L., Toksvig-Larsen, S., and Aspenberg, P. Clodronate prevents prosthetic migration: a randomized radiostereometric study of 50 total knee patients. Acta Orthop Scand 71, 553, 2000.
158. Stadelmann, V., Gauthier, O., Terrier, A., Bouler, J., and Pioletti, D. Implants delivering bisphosphonate locally increase periprosthetic bone density in an osteoporotic sheep model. A pilot study. Eur Cell Mater 16, 10, 2008.
159. Yoshinari, M., Oda, Y., Ueki, H., and Yokose, S. Immobilization of bisphosphonates on surface modified titanium. Biomaterials 22, 709, 2001.
160. Furuya, N., Hayakawa, T., Yamanishi, Y., Fukushima, T., Yoshinari, M., and Sato, M. Effect of Bisphosphonate immobilization of apatite coated titanium web on trabecular bone response. J Oral Tissue Engin 7, 73, 2009.
161. Aberg, J., Brohede, U., Mihranyan, A., Stromme, M., and Engqvis, H. Targeted Local Delivery of Bisphosphonate from Orthopaedic Implants. Key Eng Mater 396-398, 543, 2009.
162. Greiner, S., Kadow-Romacker, A., Wildemann, B., Schwabe, P., and Schmidmaier, G. Bisphosphonathes incorporated in a poly(D,L-lactide) implant coating inhibit osteoclast like cells in vitro. J Biomed Mater Res A 83, 1184, 2007.
163. Gao, Y., Luo, E., Hu, J., Xue, J., Zhu, S., and Li, J. Effect of combined local treatment with zoledronic acid and basic fibroblast growth factor on implant fixation in ovariectomized rats. Bone 44, 225, 2009.
164. Gao, Y., Zou, S., Liu, X., Bao, C., and Hu, J. The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized rats. Biomaterials 30, 1790, 2009.
165. McLeod, K., Anderson, G., Dutta, N., Smart, R., Voelcker, N., Sekel, R., and Kumar, S. Adsorption of a bisphosphonate onto hydroxyapatite using a novel co-precipitation technique for bone growth enhancement. J Biomed Mater Res A 79, 271, 2006.
166. Marx, R. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61, 1115, 2003.
167. Ruggiero, S.L., Mehrotra, B., Rosenberg, T.J., and Engroff, S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62, 527, 2004.
168. Hellstein, J.W., and Marek, C.L. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 63, 682, 2005.
169. Marx, R.E., Sawatari, Y., Fortin, M., and Broumand, V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63,
170. Hellstein, J.W., and Marek, C.L. Bisphosphonate induced osteochemonecrosis of the jaws: an ounce of prevention may be worth a pound of cure. Spec Care Dentist 26, 8, 2006.
171. Woo, S.B., Hellstein, J.W., and Kalmar, J.R. Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144, 753, 2006.
172. Dannemann, C., Grä tz, K.W., Riener, M.O., and Zwahlen, R.A. Jaw osteonecrosis related to bisphosphonate therapy a severe secondary disorder. Bone 40, 828, 2007.
173. Castro, C., Sánchez, E., Delgado, A., Soriano, I., Núñ ez, P., Baro, M., Perera, A. & É vora, C. Ciprofloxacin implants for bone infection. In vitro-in vivo characterization. J Control Release 93, 341, 2003.